01 Industry overview
The medical supplies industry at a glance
The global medical device and supplies industry is estimated at $570.0 billion in 2026, with growth increasingly concentrated in digital, robotic, cardiovascular, diabetes and other technology-intensive product areas.
- $570.0B[23]
- Global market estimate, 2026
- 6.2%[23]
- Forecast CAGR, 2025–2030
- 329,700[5]
- U.S. manufacturing jobs, 2025
- 35.2%[23]
- North America share, 2025
- Market size
- The global medical device market was valued at $540.3 billion in 2025, according to a Frost & Sullivan estimate cited in a 2026 SEBI industry report. The report forecasts the market at $570.0 billion in 2026.[23]
- Forecast & CAGR
- Frost & Sullivan estimates a 6.2% compound annual growth rate for the global medical device market from 2025 to 2030, taking the market from $540.3 billion to $729.8 billion.[23]
- Market share & regions
- North America held the largest regional share in 2025 at 35.2%, followed by Europe at 26.2% and Asia-Pacific at 23.0%. Their estimated 2025 market values were $190.2 billion, $141.6 billion and $124.3 billion, respectively.[23]
- Segmentation
- By product segment, cardiovascular devices accounted for 12.5% of the global market in 2025, followed by diagnostic imaging at 10.2%, orthopedics at 9.6%, ophthalmology at 8.4%, drug-delivery devices at 6.9% and endoscopy devices at 6.3%.[23]
- Key players & concentration
- The U.S. Census Bureau profile identifies 8,825 employer establishments in the Medical Equipment and Supplies Manufacturing industry group. A comparable market-wide concentration ratio was not available from the reliable sources reviewed.[18]
- Pricing
- The producer price index for U.S. medical equipment and supplies manufacturing was 137.868 in January 2025, with the index based on the industry series published by the Bureau of Labor Statistics through FRED.[5]
- Trends, drivers & challenges
- EY reported that global MedTech revenue reached $584 billion in 2025 and identified pulse-field ablation, structural heart, robotics, diabetes and orthopedics as high-growth areas. Trade uncertainty and tariff pressure remained material challenges, while companies were using AI to strengthen supply-chain resilience.[24]
- M&A
- Global MedTech M&A spending totaled $38.8 billion in 2025, while the average deal size reached $497 million, up 11% from 2024 and 72% above the average for the previous decade. EY also reported 36 deals worth $20.5 billion in the first half of 2025.[24]
- Regulation
- The FDA classifies medical devices into Class I, Class II and Class III according to risk, with controls increasing from general controls to general and special controls and, for many Class III devices, premarket approval. From February 2, 2026, the FDA began using its QMSR-aligned inspection program and discontinued the previous QSIT inspection approach.[21]
- Latest news
- On November 6, 2026, the FDA published a discussion paper seeking feedback on benefit-risk evaluation for robotic medical devices using autonomous or remote teleoperation capabilities. The agency also updated its Quality Management System Regulation frequently asked questions and medical-device cybersecurity materials on November 5, 2026.[21]
02 Ranking
Top 10 Companies in the Medical Supplies Industry
The leading companies in the medical supplies industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 20, 2026 · Next review December 20, 2026
Medline stands out for medical-surgical supply chain coverage because its segment delivers 11.5% revenue growth, while Johnson & Johnson focuses on surgical, vision and cardiovascular care since its MedTech segment generated $33.8 billion in 2025 sales across surgery, vision and cardiovascular care.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in surgical and procedural supplies
Medline
US
Ranked #1 · 9.4 · Surgical and procedural supplies
Why we picked it: Its medical-surgical products and supply chain segment targets hospital purchasing needs with an 11.5% revenue growth.
Leader in cardiovascular and blood products
Johnson & Johnson
US
Ranked #2 · 9.3 · Cardiovascular and blood products
Why we picked it: Its MedTech scale spans surgery, vision, and cardiovascular care, with $33.8 billion in 2025 sales.
Leader in orthopaedic and sports care products
Smith+Nephew
GB
Ranked #4 · 8.8 · Orthopaedic and sports care products
Why we picked it: Its wound care and orthopaedics and sports medicine focus is reflected in a 12.9% operating margin.
Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.
Full ranking
| # | Company | Overall ↓ | Impact | Performance | Momentum | Innovation | Company snapshot |
|---|---|---|---|---|---|---|---|
| 1 | Medline Surgical and procedural supplies · US | 9.4 | 9.3 | 9.9 | 9.9 | 9.1 | |
Company snapshot · Medline · Data as of November 20, 2026 Largest provider of medical-surgical products and supply chain solutions.[25]
| |||||||
| 2 | Johnson & Johnson Cardiovascular and blood products · US | 9.3 | 9.9 | 8.6 | 9.2 | 9.9 | |
Company snapshot · Johnson & Johnson · Data as of November 20, 2026 Its MedTech segment generated $33.8 billion in 2025 sales across surgery, vision and cardiovascular care.[26]
| |||||||
| 3 | Terumo Cardiovascular and blood products · JP | 9.0 | 8.8 | 9.3 | 9.3 | 9.1 | |
Company snapshot · Terumo · Data as of November 20, 2026 Terumo manufactures and sells blood bags, disposable devices, cardiovascular systems and dialysis products.[27]
| |||||||
| 4 | Smith+Nephew Orthopaedic and sports care products · GB | 8.8 | 8.3 | 8.5 | 9.6 | 9.7 | |
Company snapshot · Smith+Nephew · Data as of November 20, 2026 Smith+Nephew develops and manufactures products for wound care, orthopaedics and sports medicine.[28]
| |||||||
| 5 | Solventum Wound care supplies · US | 8.7 | 8.5 | 9.3 | 7.6 | 8.7 | |
Company snapshot · Solventum · Data as of November 20, 2026 Solventum's MedSurg segment includes wound therapy, dressings, IV site management and surgical supplies.[29]
| |||||||
| 6 | Convatec Wound, ostomy, continence and infusion care · GB | 8.7 | 7.9 | 8.6 | 9.6 | 9.1 | |
Company snapshot · Convatec · Data as of November 20, 2026 Convatec makes medical products for advanced wound, ostomy, continence and infusion care.[30]
| |||||||
| 7 | B. Braun Infusion, injection, dialysis and surgical products · DE | 8.5 | 9.0 | 7.8 | 8.6 | 8.0 | |
Company snapshot · B. Braun · Data as of November 20, 2026 B. Braun is a leading medical technology company supplying products across hospital care and surgery.[31]
| |||||||
| 8 | BD Syringes, injection, diagnostics and medical devices · US | 8.5 | 8.9 | 8.2 | 8.2 | 8.1 | |
Company snapshot · BD · Data as of November 20, 2026 BD delivers billions of medical products annually across medication delivery, diagnostics and intervention.[32]
| |||||||
| 9 | Teleflex Vascular, interventional and surgical devices · US | 8.2 | 7.0 | 9.3 | 8.9 | 8.1 | |
Company snapshot · Teleflex · Data as of November 20, 2026 Teleflex develops and manufactures vascular, interventional and surgical medical products.[33]
| |||||||
| 10 | Mölnlycke Wound care, surgical solutions and gloves · SE | 8.0 | 7.8 | 7.3 | 8.9 | 7.7 | |
Company snapshot · Mölnlycke · Data as of November 20, 2026 Mölnlycke is a world-leading MedTech company specializing in wound care and surgical procedures.[34]
| |||||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
- Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
- Momentum (20%): growth trajectory and future potential.
- Innovation (15%): R&D intensity and how technologically advanced the company is.
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 20, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Marie Larsen. (2026, February 13). Top 10 companies in the medical supplies industry. In Medical Supplies Industry Statistics. Gitnux. https://gitnux.org/medical-supplies-industry-statistics/#top-companies
South Korea total medical device exports
South Korea total medical device exports fell from $8.6B in 2021 to $5.3B in 2024.
03 Trends & forecasts
Top 10 Medical Supplies Industry Trends & Forecasts 2027
What is changing in the medical supplies industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01Global growth remains technology-led
High confidenceThe global medical device market was estimated at $540.3 billion in 2025 and $570.0 billion in 2026 in the supplied industry overview. Frost & Sullivan forecasts a 6.2% CAGR from 2025 to 2030, implying a market of approximately $729.8 billion by 2030.[24]
Forecast 2027: In 2027, industry expansion should remain close to the mid-single-digit range, with digital, cardiovascular, diabetes, robotics and other technology-intensive categories growing faster than basic supplies. Confidence is high because the supplied market forecast and EY’s 2025 revenue outlook point in the same direction.
02Ageing populations lift device demand
High confidenceThe World Health Organization estimates that 1.1 billion people were aged 60 or older in 2023 and projects 1.4 billion by 2030. By 2030, one in six people globally is expected to be at least 60 years old.[35]
Forecast 2027: In 2027, ageing should continue increasing demand for implants, mobility aids, monitoring equipment, diagnostics, wound care and products supporting chronic-care management. Growth should be strongest in markets expanding access to care for older adults.
03Diabetes devices expand steadily
High confidenceWHO reports that 830 million people were living with diabetes in 2022, up from 200 million in 1990, and that 14% of adults aged 18 and older had diabetes in 2022. The supplied overview also identifies diabetes as one of EY’s high-growth MedTech areas.[35][24]
Forecast 2027: In 2027, continuous glucose monitors, insulin pumps, connected meters and related consumables should grow faster than the broader supplies market. Competition will increasingly center on sensor accuracy, interoperability, reimbursement and ease of home use.
04Cardiovascular products outperform broadly
High confidenceCardiovascular devices represented 12.5% of the global market in 2025 in the supplied overview, the largest listed product segment. EY also identified structural heart and pulse-field ablation among the sector’s high-growth areas.[24]
Forecast 2027: In 2027, cardiovascular supplies should continue to outpace commodity medical products as providers adopt minimally invasive interventions, structural-heart systems and newer ablation technologies. Demand should favor products that shorten procedures and reduce hospital stays.
05AI-enabled devices move into scale-up
High confidenceThe FDA reported that more than 1,600 AI-enabled medical devices had been authorized for marketing in the United States as of September 2026. The agency also sought feedback in 2026 on a regulatory approach for generative-AI-enabled devices.[21]
Forecast 2027: In 2027, AI adoption should broaden from image analysis into workflow automation, clinical decision support, monitoring and supply-chain planning. Growth will be constrained where manufacturers cannot demonstrate explainability, clinical validation, cybersecurity and control of model updates.
06Robotics face tighter evidence requirements
Medium confidenceThe FDA published a November 2026 discussion paper seeking feedback on benefit-risk evaluation for robotic medical devices with autonomous or remote-teleoperation capabilities. The supplied overview also identifies robotics as a high-growth MedTech area.[21][24]
Forecast 2027: In 2027, robotic surgery and teleoperated systems should continue gaining investment, but commercialization will favor supervised or narrowly autonomous applications rather than unrestricted autonomy. Manufacturers will need stronger evidence on human oversight, failure modes and real-world performance.
07Cybersecurity becomes a product requirement
High confidenceIn February 2026, the FDA issued final cybersecurity guidance covering device design, labeling and documentation for premarket submissions involving cybersecurity risk. The guidance also addresses statutory requirements for cyber devices under section 524B of the FD&C Act.[21]
Forecast 2027: In 2027, cybersecurity engineering, vulnerability disclosure, software bills of materials and postmarket patching should become more important differentiators in connected-device tenders. Cybersecurity costs will rise, particularly for networked, implantable and remotely managed equipment.
08QMSR raises compliance alignment
High confidenceThe FDA’s Quality Management System Regulation became effective on February 2, 2026, incorporating ISO 13485:2016 by reference and replacing the previous inspection approach with a QMSR-aligned program. The change harmonizes U.S. quality requirements more closely with international practice.[21]
Forecast 2027: In 2027, suppliers should face continued spending on quality-system remediation, audit readiness, supplier controls and documentation. Companies already operating to ISO 13485 should have an advantage in multinational launches and contract-manufacturing bids.
09Supply chains remain strategically diversified
Medium confidenceEY reported that trade uncertainty and tariff pressure remained material challenges for MedTech companies in 2025, while companies used AI to strengthen supply-chain resilience. The sector’s broad product mix also leaves manufacturers exposed to shortages in electronics, components, sterile materials and specialized inputs.[24]
Forecast 2027: In 2027, manufacturers should continue dual sourcing, regional qualification of suppliers, higher safety stocks for critical components and greater use of supply-chain analytics. These measures will improve resilience but keep procurement and inventory costs above pre-disruption norms.
10M&A shifts toward larger platforms
High confidenceEY reported $38.8 billion of global MedTech M&A spending in 2025. The average deal size reached $497 million, 11% above 2024 and 72% above the average for the preceding decade; venture-capital investment also increased 16%.[24]
Forecast 2027: In 2027, acquisition activity should remain focused on platforms in cardiovascular care, robotics, diabetes, diagnostics, software and enabling technologies. Larger companies are likely to prefer targeted bolt-ons that add differentiated products or recurring software revenue.
04 Statistics
Technology
U.S. automation adoption is split: 38.8% report fully or partially integrated automation in 2025, while 31.4% report no current automation. Manufacturing automation is also being built internally by 53% in 2024.
Automation and robotics in the medical supplies industry
- 38.8% of surveyed U.S. medical-product manufacturers reported fully or partially integrated automation in 2025; 29.6% reported limited use for specific tasks.[1]
- 53% of surveyed healthcare and medical-device decision-makers were developing manufacturing automation internally in 2024, while 28% planned to outsource it.[2]
- 31.4% of surveyed U.S. medical-product manufacturers reported no current automation in 2025.[1]
05 Statistics
Market Intelligence
Supply value remains concentrated in disposables and clinical use: the global medical supplies market is $150.40 billion in 2025, and the U.S. medical supplies market is $68.40 billion in 2025. Distributors also hold $50 billion of inventory in 2024.
Market size, volume and shipments in the medical supplies industry
- $150.40 billion was the global medical supplies market in 2025, covering PPE, wound-care, infusion and injection, diagnostic, surgical-disposable and related supplies; value measure, worldwide.[3]
- $68.40 billion was the U.S. medical supplies market in 2025, covering disposable single-use supplies, wound care, infection-control and sterilisation products, and other supplies; value measure, United States.[4]
- $82.737 billion was U.S. medical equipment and supplies manufacturing output in 2025, measured as an annual industrial-production output index series converted to millions of dollars; NAICS 3391.[5]
Forecast growth and shipments in the medical supplies industry
- The global medical supplies market is projected to reach $236.88 billion in 2034 from $157.26 billion in 2026, a 5.3% CAGR over 2026–2034; value measure, worldwide.[3]
- The U.S. medical supplies market is forecast to grow at a 6.0% CAGR from 2026 to 2035, reaching $122.14 billion in 2035; category covers disposable, wound-care, infection-control and related supplies.[4]
- North America’s medical supplies market is forecast to grow at 3.64% annually from 2026 to 2035; regional value forecast covers medical consumables and supplies.[6]
Company counts and size structure in the medical supplies industry
- 5,667 U.S. business locations operated in medical equipment and supplies manufacturing in 2020, up from 4,859 in 2015; classification includes NAICS 3391 and related equipment-and-supplies manufacturing.[7]
- 3,557 private establishments were recorded in U.S. surgical appliance and supplies manufacturing in 2025 Q4 under NAICS 339113; establishment count, national scope.[8]
- 326,600 employees worked in U.S. medical equipment and supplies manufacturing in 2024; employment measure under NAICS 3391.[9]
Regional split of the medical supplies industry
- North America accounted for 38.0% of global medical consumables market value in 2025, compared with 27.0% for Europe and 25.0% for Asia Pacific; regional value shares, worldwide.[6]
- North America represented 35.18% of global medical consumables and supplies value in 2025, followed by Europe at 27.63% and Asia Pacific at 25.32%; regional value shares, worldwide.[10]
- North America held 37.83% of global medical supplies market revenue in 2025; regional value share, with the publisher grouping North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.[3]
06 Statistics
Strategy & Growth
Deal activity stays material in medtech-adjacent categories: global MedTech M&A spending totaled $38.8 billion in 2025, with the average deal size at $497 million.
M&A and consolidation in the medical supplies industry
- $121 million was the median upfront payment for medical-device and adjacent medtech acquisitions worldwide in 2024, down from 2023, according to DealForma data.[11]
- 41 medtech acquisitions worth $32.2 billion were recorded in 2024, according to S&P Capital IQ and Deloitte analysis; the scope includes medical technology rather than medical supplies alone.[12]
- Medical-technology M&A value rose from $19.4 billion in 2023 to $32.2 billion in 2024, while deal count fell from 59 to 41, according to S&P Capital IQ and Deloitte analysis.[12]
- 305 announced transactions involving medical devices and adjacent medtech categories generated more than $63.1 billion in total value worldwide in 2024, according to DealForma data compiled by J.P. Morgan.[11]
07 Statistics
Operating Benchmarks
Operational gains show up in productivity and output: labor productivity rose 8.5% in 2024, output increased 1.7% in 2024, and unit labor costs fell 3.3%.
Core operating metrics in the medical supplies industry
- Unit labor costs in U.S. medical equipment and supplies manufacturing fell 3.3% in 2024; BLS annual industry productivity release, NAICS 3391.[9]
- Labor productivity in U.S. medical equipment and supplies manufacturing rose 8.5% in 2024; BLS defines the industry as NAICS 3391 and reports annual productivity change.[9]
- Output in U.S. medical equipment and supplies manufacturing increased 1.7% in 2024; output is the BLS industry productivity measure for NAICS 3391.[9]
- Hours worked in U.S. medical equipment and supplies manufacturing increased 5.0% in 2024; hours are the BLS annual productivity denominator for NAICS 3391.[9]
08 Statistics
Product & Standards
Biological-safety and genotoxicity standards are expanding through 2026 editions: ISO 10993-3:2026 defines genotoxicity, carcinogenicity, reproductive toxicity and developmental toxicity, published in August 2026.
Standards, grades and specs for medical supplies
- 41 pages define ISO 10993-3:2026, edition 4, for evaluating genotoxicity, carcinogenicity, reproductive toxicity and developmental toxicity in medical devices; the edition was published in August 2026.[13]
- 42 pages define the 2025 sixth edition of ISO 10993-1 for biological-safety evaluation of medical devices; the standard was published in November 2025 by ISO for international application.[13]
- 42 pages define ISO 10993-1:2025, whose sixth edition reorganizes medical-device biological-safety requirements around ISO 14971 risk management and adds guidance on exposure duration and materials characterization.[13]
09 Statistics
Production & Operations
Quality tracking practices vary, with 22.1% of surveyed life-science quality professionals using rework or first-pass yield as a KPI in 2024. Inventory turns also differ by brand, at 15 days versus 30 days for generic products in 2024.
Defects and conformance in the medical supplies industry
- 22.1% of life-science quality professionals tracked rework or first-pass yield as a KPI in 2024, covering the medical-device and broader life-science manufacturing population surveyed.[14]
- More than 85% rework and less than 4% first-pass yield were reported for one regulated medical-device manufacturer during 2016–2025; the study describes the manufacturer anonymously as Alpha.[15]
- 32.6% of life-science quality professionals tracked defects or faults as a quality KPI in 2024, covering the medical-device and broader life-science manufacturing population surveyed.[14]
Inventory and channel stock in the medical supplies industry
- Healthcare distributors held $50 billion of inventory in 2024, covering medical supplies and other healthcare products distributed in the United States.[16]
- Branded healthcare products averaged 15 days on distributors’ shelves in 2024, compared with 30 days for generic products in the United States.[16]
- 22 days of inventory were held on average by U.S. healthcare distributors in 2024, down from 23 days in 2023.[16]
10 Statistics
People & Workforce
Workforce levels and incident rates are measurable: 332,500 employees worked in U.S. medical equipment and supplies manufacturing in December 2025, while OSHA recorded 1.5 total recordable injury and illness cases per 100 full-time workers in 2024.
Employment and hiring in the medical supplies industry
- 332,500 employees worked in U.S. medical equipment and supplies manufacturing (NAICS 3391) in December 2025, measured in thousands of employees.[9]
- 199,400 production and nonsupervisory employees worked in U.S. medical equipment and supplies manufacturing in December 2025, measured in thousands of employees.[9]
- 150,300 women were employed in U.S. medical equipment and supplies manufacturing in July 2025, measured in thousands of employees.[9]
Wages and labour costs in the medical supplies industry
- Average hourly earnings were $40.50 for all employees in U.S. medical equipment and supplies manufacturing in the latest period shown for 2025.[9]
- Average hourly earnings were $36.21 in U.S. medical equipment and supplies manufacturing in the latest period shown for 2025.[9]
- Average weekly earnings were $1,462.88 for U.S. production and nonsupervisory employees in medical equipment and supplies manufacturing in the latest period shown for 2025.[9]
Workplace safety in the medical supplies industry
- Federal OSHA issued 65 citations across 17 inspections and assessed $253,676 in penalties for U.S. medical equipment and supplies manufacturing establishments from October 2024 through September 2025.[17]
- U.S. medical equipment and supplies manufacturing recorded 1.5 total recordable injury and illness cases per 100 full-time workers in 2024.[9]
- U.S. medical equipment and supplies manufacturing recorded 0.3 cases involving days away from work per 100 full-time workers in 2024.[9]
- U.S. medical equipment and supplies manufacturing recorded 0.8 cases with days away from work, job transfer or restriction per 100 full-time workers in 2024.[9]
11 Statistics
Customers & Channel
Wholesale flows show scale across branches and merchant wholesalers in 2024: $228.440 billion through merchant wholesalers excluding manufacturers’ branches and offices, plus $340.372 billion across all merchant wholesalers.
Distribution channels for medical supplies
- $111.932 billion in 2024 sales came through manufacturers’ sales branches and offices in U.S. medical, dental, and hospital equipment and supplies wholesale; classification: 2017 NAICS 423450.[18]
- $228.440 billion in 2024 sales came through U.S. merchant wholesalers excluding manufacturers’ sales branches and offices; classification: 2017 NAICS 423450.[18]
- $340.372 billion in 2024 sales flowed through U.S. medical, dental, and hospital equipment and supplies merchant wholesalers across all establishments; classification: 2017 NAICS 423450.[18]
12 Statistics
Pricing & Finance
Instrument pricing indices increased by March 2026: surgical and medical instruments reached 156.499 in March 2026, up from 154.347 in November 2025.
Prices and price indices for medical supplies
- The U.S. producer price index for surgical and medical instruments was 156.499 in March 2026, up from 154.347 in November 2025; product code 339112-0, index base June 1982=100.[9]
- The U.S. producer price index for surgical and orthopedic instruments was 118.594 in March 2026, up from 118.223 in November 2025; product code 339112-01, index base June 2012=100.[9]
- The U.S. producer price index for surgical and medical instrument manufacturing was 161.757 in March 2026, up from 159.452 in November 2025; classification: NAICS 339112, index base June 1982=100.[9]
- The U.S. producer price index for primary products of surgical and medical instrument manufacturing was 163.304 in March 2026, up from 161.058 in November 2025; product code 339112-P, index base June 1982=100.[9]
Capex and investment in the medical supplies industry
- Medical equipment and supplies companies recorded $1.259 billion in 2022 domestic capital expenditures for company-performed R&D; classification: NAICS 3391.[19]
- Medical equipment and supplies companies recorded $11.416 billion in 2022 domestic capital expenditures; classification: NAICS 3391, covering property, plant, equipment, and identifiable intangible assets.[19]
- Medical equipment and supplies companies worldwide recorded $17.410 billion in 2022 capital expenditures; classification: NAICS 3391, including property, plant, equipment, and identifiable intangible assets.[19]
- Medical equipment and supplies companies recorded $16.223 billion in 2022 foreign capital expenditures; classification: NAICS 3391, covering property, plant, equipment, and identifiable intangible assets.[19]
13 Statistics
Trade & Footprint
Cross-border movement remains visible at the HS 9018, 9019, 9021, and 9022 grouping: Australia exported $2.787 billion and imported $5.553 billion in 2025.
Imports and exports of medical supplies
- Australia exported US$2.787 billion of medical equipment and supplies in 2025 under HS 9018, 9019, 9021 and 9022.[20]
- Australia imported US$5.553 billion of medical equipment and supplies in 2025 under HS 9018, 9019, 9021 and 9022.[20]
- The United States supplied US$1.4 billion, nearly 40% of Canada’s medical-device imports, in 2024; the category includes diagnostic imaging, orthopedics and surgical instruments under HS 9018 and 9021.[20]
14 Statistics
Regulation & Risk
FDA actions during 2020–2024 were largely manufacturer-initiated: 96% of 3,934 medical-device recalls were manufacturer-identified and voluntarily started. Fees also define regulatory cost, including $28,653 for a 510(k) fee in fiscal 2027.
Regulations and compliance for medical supplies
- US$191,020 was the standard FDA De Novo classification-request fee in fiscal year 2027; qualified small businesses paid US$47,755.[21]
- US$28,653 was the standard FDA 510(k) premarket-notification fee in fiscal year 2027; qualified small businesses paid US$7,163.[21]
- US$636,732 was the standard FDA fee for a PMA, PDP, PMR or device BLA in fiscal year 2027; qualified small businesses paid US$159,183.[21]
- US$13,785 was the annual establishment-registration fee for most U.S. medical-device establishments in FDA fiscal year 2027 under MDUFA VI.[21]
Enforcement and penalties in the medical supplies industry
- 4% of 3,934 U.S. medical-device recalls initiated during fiscal years 2020–2024 followed FDA identification of the problem and manufacturer-initiated voluntary action.[22]
- 1,017 medical-device recalls were recorded by FDA in U.S. fiscal year 2024, compared with 333 biologics recalls and 318 drug recalls.[21]
- 96% of 3,934 U.S. medical-device recalls initiated during fiscal years 2020–2024 were manufacturer-identified and voluntarily started.[22]
Key questions about the Medical Supplies Industry
What is the 2026 size of the global medical device and supplies industry?
How fast is the medical device market projected to grow from 2025 to 2030?
Which companies lead the medical supplies industry?
How widely is manufacturing automation being used by U.S. medical-product makers?
How does the U.S. wholesale channel structure show up in sales figures?
What regulatory shift affected device quality oversight starting in 2026?
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
Marie Larsen. (2026, February 13). Medical Supplies Industry Statistics. Gitnux. https://gitnux.org/medical-supplies-industry-statistics
Marie Larsen. "Medical Supplies Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/medical-supplies-industry-statistics.
Marie Larsen. 2026. "Medical Supplies Industry Statistics." Gitnux. https://gitnux.org/medical-supplies-industry-statistics.
Sources & references
35 sources cited across this report
go.ascentialtech.com
jabil.com
fortunebusinessinsights.com
emergenresearch.com
fred.stlouisfed.org
credenceresearch.com
maine.gov
beautifydata.com
bls.gov
pmarketresearch.com
jpmorgan.com
deloitte.com
iso.org
qualio.com
ieeexplore.ieee.org
hda.org
osha.gov
data.census.gov
ncses.nsf.gov
trade.gov
fda.gov
files.gao.gov
- sebi.gov.in
ey.com
medline.com
jnj.com
- terumomedical.com
smith-nephew.com
investors.solventum.com
convatecgroup.com
bbraun.com
investors.bd.com
teleflex.com
molnlycke.com
who.int
